Literature DB >> 30126582

The Pharmacoeconomic Aspects of Antibiotic Stewardship Programs.

Cheston B Cunha1.   

Abstract

Optimal antimicrobial therapy must take into account the key factors in antibiotic selection, that is, spectrum, tissue penetration, resistance potential, safety profile, and relative cost-effectiveness. The least expensive drug is usually accompanied by other concerns, such as high resistance potential, poor side effect profile, pharmacokinetic properties that limit penetration into target tissue (site of infection), and/or suboptimal activity against the presumed/known pathogen. It is false economy to preferentially select the least expensive antibiotics solely because of its acquisition cost. Therapeutic failure and hidden costs may make an apparently less expensive antibiotic most costly in the end.
Copyright © 2018 Elsevier Inc. All rights reserved.

Keywords:  Antimicrobial stewardship; Cost; Oral antibiotic therapy; Pharmacoeconomics

Mesh:

Substances:

Year:  2018        PMID: 30126582     DOI: 10.1016/j.mcna.2018.05.010

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  3 in total

Review 1.  Global research publications on irrational use of antimicrobials: call for more research to contain antimicrobial resistance.

Authors:  Waleed M Sweileh
Journal:  Global Health       Date:  2021-08-24       Impact factor: 4.185

Review 2.  It's about the patients: Practical antibiotic stewardship in outpatient settings in the United States.

Authors:  Alpesh N Amin; E Patchen Dellinger; Glenn Harnett; Bryan D Kraft; Kerry L LaPlante; Frank LoVecchio; James A McKinnell; Glenn Tillotson; Salisia Valentine
Journal:  Front Med (Lausanne)       Date:  2022-07-27

3.  Consumption of Antibiotics and Epidemiology of Clostridioides difficile in the European Union in 2016-Opportunity for Practical Application of Aggregate ECDC Data.

Authors:  Estera Jachowicz; Anna Różańska; Monika Pobiega; Mariusz Topolski; Jadwiga Wójkowska-Mach
Journal:  Antibiotics (Basel)       Date:  2020-03-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.